wire - news in brief
« BACK
Pharmacology - Health - 08:00
Health - Pharmacology - 29.07.2020
Pharmacology - 27.07.2020
Pharmacology - Health - 27.07.2020
Pharmacology - Health - 24.07.2020
Pharmacology - Health - 23.07.2020
Pharmacology - Economics / Business - 21.07.2020
Health - Pharmacology - 16.07.2020
Health - Pharmacology - 15.07.2020 
Drones to Deliver Tuberculosis Drugs in Madagascar
The use of drones in global health settings has rapidly evolved in the past years. As drone technology continues to expand beyond the military and recreational sectors, it is foreseen that it will have a significant role to play in healthcare delivery.
Pharmacology - Health - 13.07.2020
Pharmacology - Health - 10.07.2020
Pharmacology - Health - 07.07.2020
Health - Pharmacology - 06.07.2020 
"We have the here and now. That’s all we really have."
Acceptance and Commitment Therapy (ACT) is still a relatively young approach from behavioral therapy, but has already proven itself in the treatment of a wide range of mental disorders.
Pharmacology - Health - 01.07.2020
Pharmacology - Economics / Business - 01.07.2020
Health - Pharmacology - 30.06.2020 
Meeting challenges through basic research
Many scientists are currently undertaking work on the Sars-CoV-2 virus. But hundreds of projects supported by the SNSF are already contributing to finding answers to the current health crisis. In Switzerland and around the world, the novel coronavirus has become a priority for scientific research. Projects supported by the Swiss National Science Foundation (SNSF) are no exception.
Pharmacology - Health - 29.06.2020
Pharmacology - Health - 29.06.2020
Pharmacology - Health - 26.06.2020
Pharmacology - Health - 26.06.2020
Health - Pharmacology - 24.06.2020
Health - Pharmacology - 23.06.2020 
Breast Cancer Diagnostics: Spin-off Artidis announces successful clinical trial
The company Artidis, a University of Basel spin-off, has announced that it developed a test procedure that can detect breast cancer with a very high sensitivity. This is demonstrated by a clinical trial that investigated whether a nanomechanical biomarker of tissue samples is suitable for the diagnosis of breast cancer.
Health - Pharmacology - 22.06.2020
Pharmacology - Health - 19.06.2020
Pharmacology - Life Sciences - 19.06.2020
Health - Pharmacology - 18.06.2020
Pharmacology - Health - 17.06.2020
Pharmacology - Health - 11.06.2020
Pharmacology - Health - 05.06.2020
Pharmacology - Health - 04.06.2020
Pharmacology - Health - 04.06.2020 
The key lies in the genes
Whether or not patients will respond to a drug can be determined in advance. In this way, side effects can be avoided and patients benefit, writes Ernst Hafen. "All things are poison, and nothing is without poison, the dosage alone makes it so a thing is not a poison." These were the words of Paracelsus, a Swiss physician who recognised back in the 16 th century that every medicine has its benefits and risks, and that for a medicine to work, the individual dose is crucial.
Pharmacology - 02.06.2020
Health - Pharmacology - 30.05.2020 
Switzerland's lockdown has sharply reduced the cases of COVID-19
EPFL researchers have modeled the effects of measures taken in the country to slow the spread of coronavirus. According to their estimates, the contamination rate has fallen by between 53% and 92%, depending on the canton, and people's movements have been reduced by 30% to 80%. Have the Swiss government's lockdown measures been effective in stemming the pandemic? That's the question a team of EPFL researchers set out to answer by analyzing data dating back to 28 February, the day the Swiss government banned groupings of over 1,000 people.
Pharmacology - Health - 29.05.2020
Pharmacology - Health - 29.05.2020
Pharmacology - Health - 28.05.2020
Pharmacology - Health - 28.05.2020
Pharmacology - Health - 27.05.2020
Pharmacology - Health - 27.05.2020
Health - Pharmacology - 19.05.2020
Pharmacology - Health - 19.05.2020
Pharmacology - Health - 14.05.2020
Pharmacology - 07.05.2020 
Flowbone can help prevent bone fractures caused by osteoporosis
EPFL scientists have developed a gel that can locally reinforce bones weakened by osteoporosis. The startup they created, called Flowbone, has just made it through the second round of the Venture Kick competition. Femoral neck fractures occur frequently among the elderly, and are usually caused by osteoporosis - a disease that weakens the bone structure.
Pharmacology - Health - 06.05.2020
Pharmacology - Health - 01.05.2020
Pharmacology - Health - 29.04.2020
Pharmacology - Economics / Business - 28.04.2020
Pharmacology - Health - 23.04.2020 
Possible coronavirus drug: university pharmacists produce generic medication
In response to a lack of potential coronavirus medications on the market, pharmacists from the University of Basel have begun to produce tablets themselves.
Health - Pharmacology - 23.04.2020 
Trial Launched to Test Prophylactic Treatments for COVID-19 Contact Persons
With the easing of measures, there is a pressing need for tools and approaches to contain potential new COVID-19 outbreaks.
Pharmacology - Health - 22.04.2020
Pharmacology
Results 1 - 50 of 1431.
Novartis Cosentyx receives EU approval for first-line systemic treatment in pediatric psoriasis
EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile 1 Modera
EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile 1 Modera
Novartis receives Piqray approval in Europe - the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs.
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs.
New Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu versus aflibercept
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept,
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept,
The use of drones in global health settings has rapidly evolved in the past years. As drone technology continues to expand beyond the military and recreational sectors, it is foreseen that it will have a significant role to play in healthcare delivery.
New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A
Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from phase III HAVEN studies, with no new safety signals identified 1,2,3 STASEY is the largest
Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from phase III HAVEN studies, with no new safety signals identified 1,2,3 STASEY is the largest
Acceptance and Commitment Therapy (ACT) is still a relatively young approach from behavioral therapy, but has already proven itself in the treatment of a wide range of mental disorders.
Many scientists are currently undertaking work on the Sars-CoV-2 virus. But hundreds of projects supported by the SNSF are already contributing to finding answers to the current health crisis. In Switzerland and around the world, the novel coronavirus has become a priority for scientific research. Projects supported by the Swiss National Science Foundation (SNSF) are no exception.
Novartis Cosentyx gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile
EMA CHMP positive opinion paves way for Cosentyx to become a first-line systemic treatment in pediatric psoriasis CHMP opinion based on two Phase III studies showing Cosentyx provides fast and stro
EMA CHMP positive opinion paves way for Cosentyx to become a first-line systemic treatment in pediatric psoriasis CHMP opinion based on two Phase III studies showing Cosentyx provides fast and stro
Novartis receives positive CHMP opinion for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps
If approved, Xolair (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-immunoglo
If approved, Xolair (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-immunoglo
The company Artidis, a University of Basel spin-off, has announced that it developed a test procedure that can detect breast cancer with a very high sensitivity. This is demonstrated by a clinical trial that investigated whether a nanomechanical biomarker of tissue samples is suitable for the diagnosis of breast cancer.
Computational pharmacology to combat the coronavirus
The ongoing COVID-19 pandemic has hit the world population hard, spreading throughout the globe since the beginning of the year and claiming more than 450,000 victims. The entire scientific community is engaged in an unprecedented effort to curb the progression of the disease, for which no specific cure is yet available.
The ongoing COVID-19 pandemic has hit the world population hard, spreading throughout the globe since the beginning of the year and claiming more than 450,000 victims. The entire scientific community is engaged in an unprecedented effort to curb the progression of the disease, for which no specific cure is yet available.
Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania
New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care Program continues progress in Ghana with more than 2000 patients bein
New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care Program continues progress in Ghana with more than 2000 patients bein
Novartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
FDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis
FDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis
US FDA approves updated Novartis Beovu label, to include additional safety information
Novartis worked with US Food and Drug Administration (FDA) to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of wet AMD patients 1 The upda
Novartis worked with US Food and Drug Administration (FDA) to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of wet AMD patients 1 The upda
Novartis PREVENT data show Cosentyx helps patients realize early and lasting relief in axial spondyloarthritis
Phase III PREVENT data show Cosentyx 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 52 1 nr-axSpA is t
Phase III PREVENT data show Cosentyx 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 52 1 nr-axSpA is t
Whether or not patients will respond to a drug can be determined in advance. In this way, side effects can be avoided and patients benefit, writes Ernst Hafen. "All things are poison, and nothing is without poison, the dosage alone makes it so a thing is not a poison." These were the words of Paracelsus, a Swiss physician who recognised back in the 16 th century that every medicine has its benefits and risks, and that for a medicine to work, the individual dose is crucial.
EPFL researchers have modeled the effects of measures taken in the country to slow the spread of coronavirus. According to their estimates, the contamination rate has fallen by between 53% and 92%, depending on the canton, and people's movements have been reduced by 30% to 80%. Have the Swiss government's lockdown measures been effective in stemming the pandemic? That's the question a team of EPFL researchers set out to answer by analyzing data dating back to 28 February, the day the Swiss government banned groupings of over 1,000 people.
Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)
Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients 1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achi
Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients 1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achi
EPFL scientists have developed a gel that can locally reinforce bones weakened by osteoporosis. The startup they created, called Flowbone, has just made it through the second round of the Venture Kick competition. Femoral neck fractures occur frequently among the elderly, and are usually caused by osteoporosis - a disease that weakens the bone structure.
Novartis Cosentyx gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum
Cosentyx is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part of the axial spondyloarthritis (axSpA) d
Cosentyx is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part of the axial spondyloarthritis (axSpA) d
In response to a lack of potential coronavirus medications on the market, pharmacists from the University of Basel have begun to produce tablets themselves.
With the easing of measures, there is a pressing need for tools and approaches to contain potential new COVID-19 outbreaks.
Novartis Kymriah receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults
If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults
